Power Law company profile

Caribou Biosciences

Biotech & Life Sciences · Berkeley, United States · Founded 2011 · IPO 2021 Unicorn

Biotechnology company focused on genome engineering and developing technology-based solutions for cells

Valuation

$74M

Market cap · May/2026

Revenue

$11M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

29 investors on Caribou Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage

Novartis

Genoa Ventures

Series B+ 23 investors entered at this stage

AbbVie

The Leukemia & Lymphoma Society

Point72 Ventures

Maverick Capital

Pontifax AgTech

Avidity Partners

Monashee Investment Management

Janus Henderson Investors

Ridgeback Capital

Avego Bioscience Capital

Heritage Medical Systems

Mission Bay Capital

LifeSci Venture Partners

University of California

Berkeley

Heritage Group

Adage Capital

Anterra Capital

Farallon Capital Management

Tekla Capital Management

PFM Health Sciences

F-Prime

Invus

Caribou Biosciences mafia

Startups founded by Caribou Biosciences alumni

Former Caribou Biosciences employees who went on to start their own companies. Sorted by Dealroom signal score.

Laguna BioEst. 2022

Jonathan KotulaUnited States

Signal score79

Vetmab BiosciencesEst. 2022

Richard ChinUnited States

Signal score71

Intellia TherapeuticsEst. 2014

Rodolphe Barrangou.United States

Signal score67

Editas MedicineEst. 2013

Jennifer A. DoudnaUnited States

Signal score62

Book a demo to explore the full alumni network →

Global footprint

Where Caribou Biosciences has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

7.6K monthly visits
across markets

🇺🇸 United States57.9%

🇨🇦 Canada21.1%

🇬🇧 United Kingdom15.8%

🇮🇳 India3.9%

🇯🇵 Japan1.3%

Top 5 markets shown

Patent intelligence

$98M patent portfolio · 35 active families

Estimated portfolio value

$98M

131.7% of market cap · 20.7× smaller than top peer Ablynx ($2B)

35 active patent families

Where Caribou Biosciences innovates Molecular biologyNucleic acidBioinformaticsCAR - Chimeric antigen receptorPolynucleotide

Where Caribou Biosciences concentrates vs peers

Each axis is a top-10 topic across Caribou Biosciences and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Caribou Biosciences

An AI-synthesized read of the highest-engagement posts about Caribou Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Caribou Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles